Mintage Scientifics holding I-Tech strengthens its commercial and industrial capabilities by appointing Oliver Weigenand as Chief Operating Officer (COO). Oliver has formerly been holding various international executive positions within LANXESS Corporation.

In the newly installed position Oliver will hold responsibility for sales and delivery and will in this position also lead the development of I-Techs industrial capabilities. Through this important reinforcement I-Tech is ready to accelerate global growth of its all new marine active agent (biocide), Selektope®.

I am very pleased that Oliver has selected I-Tech and assumed the position as COO. With Olivers passion for driving growth, his international experience from high demanding positions and deep insights in the chemical and biocidal industry, we have the best possible line up to make a difference to the market, says Philip Chaabane, CEO at I-Tech AB.

Oliver has an impressive track record from his 8 years at LANXESS Corporation and has successfully held positions as Global Product Manager (including marine biocides) and has also served as a CEO of an SME within the LANXESS Corp. Oliver recently served as Vice President North and Central America at LANXESS and moves back to Europe. Oliver assumes his role as COO at I-Tech in Gothenburg on June 15th.

I am absolutely convinced, that Selektope technology is a unique opportunity to establish a new generation marine antifouling product , says Oliver Weigenand. I am thrilled to boost global market approach and to help strengthen I-Techs industrial footprint. There are a lot of great potentials in front of the I-Tech team, together we will continue to built a strong platform, to ensure sustainable long term growth of Selektope,

For more information please contact I-Tech CEO, Philip Chaabane,

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see




Documents & Links